Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering Sells 2,366 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 2,366 shares of the company’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the sale, the chief executive officer now directly owns 137,398 shares in the company, valued at $14,274,278.22. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Grant Pickering also recently made the following trade(s):

• On Friday, November 1st, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $106.82, for a total transaction of $1,602,300.00.
• On Monday, October 7th, Grant Pickering sold 7,098 shares of Vaxcyte stock. The shares were sold at an average price of $109.21, for a total transaction of $775,172.58.
• On Friday, August 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00.

Vaxcyte Stock Up 3.9 %

Shares of NASDAQ PCVX opened at $106.67 on Friday. The firm’s 50-day moving average price is $111.04 and its 200-day moving average price is $86.92. Vaxcyte, Inc. has a 52-week low of $46.16 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter in the previous year, the firm posted ($0.91) earnings per share. As a group, equities research analysts forecast that Vaxcyte, Inc. will post -4.33 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PCVX. Darwin Global Management Ltd. lifted its stake in shares of Vaxcyte by 374.3% in the 1st quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock worth $187,907,000 after purchasing an additional 2,170,845 shares during the period. Vanguard Group Inc. grew its position in shares of Vaxcyte by 15.2% during the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after acquiring an additional 1,284,883 shares during the period. Capital Research Global Investors increased its stake in shares of Vaxcyte by 20.4% in the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after purchasing an additional 700,414 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock worth $524,117,000 after purchasing an additional 692,492 shares during the period. Finally, Avoro Capital Advisors LLC purchased a new position in Vaxcyte during the first quarter valued at $39,278,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. BTIG Research boosted their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Leerink Partners increased their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Needham & Company LLC restated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday. Jefferies Financial Group upped their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Finally, Mizuho raised their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte presently has an average rating of “Buy” and an average target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.